Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: An analysis of 18 months of follow-up data from the JMAAV study

Modern Rheumatology

Volumn 22, Issue 6, 2012, Pages 877-884

  Suka, Machi ^a   Hayashi, Taichi ^b   Kobayashi, Shigeto ^c   Ito, Satoshi ^d   Yumura, Wako ^e   Ozaki, Shoichi ^f  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d Niigata Rheumatic Center   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Birmingham Vasculitis Activity Score (BVAS); Japan; MOS short form 36 item health survey (SF 36); MPO ANCA associated vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; MYELOPEROXIDASE; PREDNISOLONE;

AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DISEASE ACTIVITY; EMOTION; FEMALE; FOLLOW UP; HUMAN; JAPANESE; MALE; MULTICENTER STUDY; MYELOPEROXIDASE ANCA ASSOCIATED VASCULITIS; NERVOUS SYSTEM; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SCORING SYSTEM; SHORT FORM 36; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; PEROXIDASE; PREDNISOLONE; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84870373133     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0602-4     Document Type: Article

References (22)

1. Chen M, Kallenberg CG. The environment, geoepidemiology and ANCA-Associated vasculitides. Autoimmun Rev. 2010;9:A293-8.
2. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67:1004-10.
3. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98:97-111.
4. Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, Gajria K, Cole JC, Becker JC, Emery P. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis. 2007;66:189-94.
5. Mittendorf T, Dietz B, Sterz R, Kupper H, Cifaldi MA, von der Schulenburg JM. Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. J Rheumatol. 2007;34:2343-50.
6. Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose-Ranging Assessment International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.
7. Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008;35:206-15.
8. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis. 2008;67:260-5.
9. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, Kerstens PJ, Peeters AJ, van Zeben D, Breedveld FC, Huizinga TW, Dijkmans BA, Allaart CF. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61:4-12.
10. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-Associated vasculitis. Ann Rheum Dis. 2007;66:605-17.
11. Merkel PA, Herlyn K, Mahr AD, Neogi T, Seo P, Walsh M, Boers M, Luqmani R. Progress towards a core set of outcome measures in small-vessel vasculitis: report from OMERACT 9. J Rheumatol. 2009;36:2362-8.
12. Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, Kurihara Y, Kurokawa MS, Makino H, Nagafuchi H, Nakabayashi K, Nishimoto N, Suka M, Tomino Y, Yamada H, Yamagata K, Yoshida M, Yumura W. Severity-based treatment for Japanese patients with MPO-ANCA-Associated vasculitis: the JMAAV study. Mod Rheumatol. 2011 (in press).
13. Ozaki S. ANCA-Associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87-96.
14. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283-92.
15. Fukuhara S, Suzukamo Y. Manual of SF-36 v2, Japanese version. Kyoto: Institute for Health Outcomes and Process Evaluation Research; 2004. (in Japanese).
16. Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D. Use of "spydergrams" to present and interpret SF-36 healthrelated quality of life data across rheumatic diseases. Ann Rheum Dis. 2009;68:1800-4.
17. Carpenter DM, Thorpe CT, Lewis M, Devellis RF, Hogan SL. Health-related quality of life for patients with vasculitis and their spouses. Arthritis Rheum. 2009;61:259-65.
18. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003;49: 826-37.
19. Newall C, Schinke S, Savage CO, Hill S, Harper L. Impairment of lung function, health status and functional capacity in patients with ANCA-Associated vasculitis. Rheumatology. 2005;44:623-8.
20. Koutantji M, Pearce S, Harrold E. Psychological aspects of vasculitis. Rheumatology. 2000;39:1173-9.
21. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44.
22. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 2005;52:2461-9.